Loading organizations...
§ Private Profile · Miami, FL, USA
clinical-stage pharmaceutical company developing therapeutics for skin diseases, focused on hyperhidrosis, atopic dermatitis, and acne.
Brickell Biotech is a clinical-stage pharmaceutical company developing prescription therapeutics for skin diseases such as hyperhidrosis, atopic dermatitis, and acne, based in Miami, Florida. The organization focuses on advancing new molecular entities, specifically its primary pipeline candidates BBI-4000 and BBI-5000, through rigorous clinical trials to target the broader global dermatology market. To finance its ongoing clinical development and corporate operations, the enterprise secured a $10 million Series C venture financing round in 2015 and subsequently completed a $20.1 million public offering on the Nasdaq in June 2020. The firm established strategic commercial partnerships with international entities like Kaken Pharmaceutical and operated under the leadership of executives including Robert B. Brown and Charlie Stiefel before officially rebranding to Fresh Tracks Therapeutics in September 2022. Brickell Biotech was originally founded in 2009 by Reginald Hardy and Andrew Sklawer.
Brickell Biotech has raised $17.0M across 2 funding rounds.
Brickell Biotech has raised $17.0M in total across 2 funding rounds.
Brickell Biotech has raised $17.0M across 2 funding rounds. Most recently, it raised $10.0M Series C in February 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 3, 2015 | $10M Series C | — | — | Announced |
| Feb 26, 2013 | $7M Series B | Paul Kang | Palisade Capital Management | Announced |
Brickell Biotech has raised $17.0M in total across 2 funding rounds.
Brickell Biotech's investors include Paul Kang, Palisade Capital Management.